Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

580 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effectiveness and Safety of Teriflunomide in Relapsing-Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study.
Meca-Lallana JE, Prieto González JM, Caminero Rodríguez AB, Olascoaga Urtaza J, Alonso AM, Durán Ferreras E, Espinosa R, Dotor J, Romera M, Ares Luque A, Pérez Ruiz D, Calles C, Hernández MA, Hervás García M, Mendoza Rodríguez A, Berdei Montero Y, Téllez N, Herrera Varó N, Sotoca J, Presas-Rodríguez S, Querol Gutierrez LA, Hervás Pujol M, Batlle Nadal J, Martín Ozaeta G, Gubieras Lillo L, Martínez Yélamos S, Ramió-Torrentà L, Mallada Frechin J, Belenguer Benavides A, Gascón-Giménez F, Casanova B, Landete Pascual L, Berenguer L, Navarro L, Gómez Gutierrez M, Durán C, Rodríguez Regal A, Álvarez E, García-Estévez DA, López Real AM, Llaneza González MA, Marzo Sola ME, Sánchez-Menoyo JL, Oterino A, Villaverde González R, Castillo-Triviño T, Álvarez de Arcaya A, Llarena C. Meca-Lallana JE, et al. Among authors: navarro l. Neurol Ther. 2023 Dec;12(6):2177-2193. doi: 10.1007/s40120-023-00557-7. Epub 2023 Oct 20. Neurol Ther. 2023. PMID: 37861931 Free PMC article.
Treatment of Multiple Sclerosis With Teriflunomide. Multicenter Study of Real Clinical Practice in the Valencian Community-Spain.
Landete L, Pérez-Miralles F, García S, Belenguer A, Gascón F, Domínguez JA, Carcelén-Gadea M, Quintanilla-Bordás C, Navarro L, Gabaldón L, Casanova B. Landete L, et al. Among authors: navarro l. Front Neurol. 2021 Oct 29;12:727586. doi: 10.3389/fneur.2021.727586. eCollection 2021. Front Neurol. 2021. PMID: 34803877 Free PMC article.
Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study.
Alcalá C, Quintanilla-Bordás C, Gascón F, Sempere ÁP, Navarro L, Carcelén-Gadea M, Landete L, Mallada J, Cañizares E, Belenguer A, Carratalá S, Domínguez JA, Pérez-Miralles FC, Gil-Perotín S, Gasqué R, Cubas L, Castillo J, Casanova B. Alcalá C, et al. Among authors: navarro l. J Neurol. 2022 Jul;269(7):3676-3681. doi: 10.1007/s00415-022-10989-0. Epub 2022 Feb 2. J Neurol. 2022. PMID: 35107597
New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab.
Toboso I, Tejeda-Velarde A, Alvarez-Lafuente R, Arroyo R, Hegen H, Deisenhammer F, Sainz de la Maza S, Alvarez-Cermeño JC, Izquierdo G, Paramo D, Oliva P, Casanova B, Agüera-Morales E, Franciotta D, Gastaldi M, Fernández O, Urbaneja P, Garcia-Dominguez JM, Romero F, Laroni A, Uccelli A, Perez-Sempere A, Saiz A, Blanco Y, Galimberti D, Scarpini E, Espejo C, Montalban X, Rasche L, Paul F, González I, Álvarez E, Ramo C, Caminero AB, Aladro Y, Calles C, Eguía P, Belenguer-Benavides A, Ramió-Torrentà L, Quintana E, Martínez-Rodríguez JE, Oterino A, López de Silanes C, Casanova LI, Landete L, Frederiksen J, Bsteh G, Mulero P, Comabella M, Hernández MA, Espiño M, Prieto JM, Pérez D, Otano M, Padilla F, García-Merino JA, Navarro L, Muriel A, Frossard LC, Villar LM. Toboso I, et al. Among authors: navarro l. Front Neurol. 2020 Dec 17;11:579438. doi: 10.3389/fneur.2020.579438. eCollection 2020. Front Neurol. 2020. PMID: 33408681 Free PMC article.
Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab.
Villar LM, Costa-Frossard L, Masterman T, Fernandez O, Montalban X, Casanova B, Izquierdo G, Coret F, Tumani H, Saiz A, Arroyo R, Fink K, Leyva L, Espejo C, Simó-Castelló M, García-Sánchez MI, Lauda F, Llufriú S, Álvarez-Lafuente R, Olascoaga J, Prada A, Oterino A, de Andrés C, Tintoré M, Ramió-Torrentà L, Rodríguez-Martín E, Picón C, Comabella M, Quintana E, Agüera E, Díaz S, Fernandez-Bolaños R, García-Merino JA, Landete L, Menéndez-González M, Navarro L, Pérez D, Sánchez-López F, Serrano-Castro PJ, Tuñón A, Espiño M, Muriel A, Bar-Or A, Álvarez-Cermeño JC. Villar LM, et al. Among authors: navarro l. Ann Neurol. 2015 Mar;77(3):447-57. doi: 10.1002/ana.24345. Epub 2015 Jan 30. Ann Neurol. 2015. PMID: 25581547
Cerebrospinal fluid mitochondrial DNA levels in patients with multiple sclerosis.
Fissolo N, Cervera-Carles L, Villar Guimerans LM, Lleó A, Clarimón J, Drulovic J, Dujmovic I, Voortman M, Khalil M, Gil E, Navarro L, Álvarez-Cermeño JC, Montalban X, Comabella M. Fissolo N, et al. Among authors: navarro l. Mult Scler. 2019 Oct;25(11):1535-1538. doi: 10.1177/1352458518786055. Epub 2018 Jul 9. Mult Scler. 2019. PMID: 29985092
Massive amorphous mass in apheresis platelet product.
Larrea L, Vera B, Gómez I, Navarro L, Castro E, Arbona C. Larrea L, et al. Among authors: navarro l. Transfusion. 2021 Dec;61(12):3293-3294. doi: 10.1111/trf.16720. Epub 2021 Nov 2. Transfusion. 2021. PMID: 34726273 No abstract available.
Transfusion-transmitted arboviruses: Update and systematic review.
Giménez-Richarte Á, Ortiz de Salazar MI, Giménez-Richarte MP, Collado M, Fernández PL, Clavijo C, Navarro L, Arbona C, Marco P, Ramos-Rincon JM. Giménez-Richarte Á, et al. Among authors: navarro l. PLoS Negl Trop Dis. 2022 Oct 6;16(10):e0010843. doi: 10.1371/journal.pntd.0010843. eCollection 2022 Oct. PLoS Negl Trop Dis. 2022. PMID: 36201547 Free PMC article.
580 results